comparemela.com

Prnewswire Scineuro Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SciNeuro Initiates Phase 1 Clinical Trial with SNP318, a Novel Lp-PLA2 Inhibitor Targeting Neurodegenerative and Inflammatory Diseases

SNP318, a novel oral Lp-PLA2 inhibitor optimized for CNS diseases, advances into human clinical trials. Systemic administration of oral Lp-PLA2 inhibitors has.

Western australiaPrnewswire scineuro pharmaceuticalsScineuro pharmaceuticalsDiabetic macularNeuro pharmaceuticals

SciNeuro Pharmaceuticals Announces the Appointment of Guojun Bu, Ph D , as Chief Scientific Officer, and Provides Update on Pipeline of Novel CNS Therapeutics

/PRNewswire/ SciNeuro Pharmaceuticals is developing novel therapeutics to address major unmet need within CNS diseases. The company is pleased to announce.

United statesMary lowell learyMayo clinic neuroregeneration labMayo clinic alzheimer disease research centerWashington university school of medicineEli lilly coDepartment of neurosciencePrnewswire scineuro pharmaceuticalsAmerican association for the advancement of scienceAlzheimer associationScineuro pharmaceuticalsMayo clinicAlpha synuclein inhibitorNeuro pharmaceuticalsChief scientificChief scientific officer

SciNeuro Pharmaceuticals Announces a License and Option Agreement with GSK to Progress Development of Novel Therapies for CNS Diseases

/PRNewswire/ SciNeuro Pharmaceuticals (SciNeuro), a leader in the discovery and development of innovative therapeutics for the treatment of CNS diseases,.

Jessie yangJohn leporeAlzheimers dementHead of researchPrnewswire scineuro pharmaceuticalsScineuro pharmaceuticalsNeuro pharmaceuticalsGreater chinaNeuro media contact

vimarsana © 2020. All Rights Reserved.